Heart Rate Reduction Is Probably Not the Main Beneficial Mechanism by Which Beta Blockade Improves Outcome in Patients With Systolic Chronic Heart Failure

American Journal of Cardiology

Volumn 102, Issue 4, 2008, Pages 506-507

  Fragasso, Gabriele ^a   Salerno, Anna ^a   Margonato, Alberto ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIAC PATIENT; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; LETTER; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; SYSTOLIC HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; CHRONIC DISEASE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; INCIDENCE; PROPANOLAMINES; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE VOLUME; TREATMENT OUTCOME;

EID: 50949089151     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.05.043     Document Type: Letter

References (7)

1. Flannery G., Gehrig-Mills R., Billah B., and Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101 (2008) 865-869
2. Wallhaus T.R., Taylor M., DeGrado T.R., and Russell D.C. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103 (2001) 2441-2446
3. Podbregar M., and Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Cardiac Fail 8 (2002) 369-378
4. Sharma V., Dhillon P., Wambolt R., Parsons H., Brownsey R., Allard M.F., and McNeill J.H. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin (STZ) diabetic rat. Am J Physiol Heart Circ Physiol 294 (2008) H1609-H1620
5. Poole-Wilson P., Swedberg K., Cleland J., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., et al., Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
6. Wiltse C., Wright T., and MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-666
7. Mobini R., Jansson P.A., Bergh C.H., Sharing Tang M., Waagstein F., and Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci 110 (2006) 329-336